Trump Considers Johns Hopkins Surgeon as Potential FDA Lead

Former President Donald Trump is reportedly considering Dr. Martin Makary, a distinguished surgeon and author affiliated with Johns Hopkins University, to potentially lead the Food and Drug Administration (FDA). This consideration was revealed by two sources familiar with the matter, as reported by Reuters on Wednesday.

Dr. Makary gained prominence during the Covid-19 pandemic for advocating the benefits of natural immunity and expressing opposition to Covid vaccine mandates. With a reputation in public health advocacy, Dr. Makary has often voiced concerns about various public health strategies and emphasized re-evaluation in medical treatments.

The FDA, regarded as the world’s most influential drug regulator, manages a substantial budget exceeding $7 billion. The agency is tasked with approving new treatments to ensure they are both safe and effective before entering the American market. Its jurisdiction extends over human and veterinary medications, medical devices, biological treatments, and vaccines. Additionally, the FDA oversees safety standards related to food, tobacco, cosmetics, and radiation-emitting products.

Brian Hughes, a spokesperson for Trump’s transition team, refrained from speculating on Dr. Makary’s potential appointment or any related announcements. If appointed, Dr. Makary would report directly to the head of the Department of Health and Human Services (HHS).

As FDA commissioner, Dr. Makary would succeed Dr. Robert Califf, who previously served in the role during the Obama administration. Dr. Califf is credited with revamping agency processes and tackling the spread of misinformation.

Dr. Makary, co-developer of the Surgery Checklist, has been recognized for his contributions that improved surgical outcomes and received international endorsement by the World Health Organization. His latest publication, «Blind Spots,» published in September, critiques what he describes as «massive overtreatment» within U.S. medical care.

Beyond his academic and clinical achievements, Dr. Makary has offered his expertise as an advisor to the conservative healthcare think tank, Paragon Health Institute, based in Washington, D.C.

His nomination would be subject to confirmation by the U.S. Senate, before he could officially take over the leadership of the FDA.